Claims
- 1. An isolated Bifidobacterium having the characteristics of strain RecB1.
- 2. An isolated Bifidobacterium having the characteristics of strain RecB4.
- 3. An isolated Bifidobacterium having the characteristics of strain J1.
- 4. An isolated Bifidobacterium having the characteristics of strain J2.
- 5. An isolated Bifidobacterium having the characteristics of strain J4.
- 6. An isolated Bifidobacterium having the characteristics of strain P1.
- 7. An isolated Bifidobacterium having the characteristics of strain 6A.
- 8. An isolated Bifidobacterium having the characteristics of strain 6A.
- 9. A method for inhibiting the replication of a microbe in the gastrointestinal tract of an animal, comprising administering to an animal a Bifidobacterium that secretes a siderophore, and measuring the presence of the microbe in the gastrointestinal tract, where a decrease in the presence of the microbe in the animal after administration of the Bifidobacterium indicates inhibition of the replication of the microbe.
- 10. The method of claim 9 further comprising growing the Bifidobacterium under iron limited conditions before administration.
- 11. The method of claim 10 wherein growing the Bifidobacterium under iron limited conditions comprises growth in the presence of an iron chelator.
- 12. The method of claim 9 wherein the animal is a human.
- 13. The method of claim 9 wherein the microbe is a prokaryotic microbe.
- 14. The method of claim 13 wherein the prokaryotic microbe is selected from the group consisting of E. coli, Salmonella spp., Shigella spp., Campylobacter spp., Clostridium difficile, and Clostridium perfringens.
- 15. The method of claim 9 wherein the gastrointestinal tract is the large intestine.
- 16. A method for treating a lactase deficiency, comprising administering to an animal a Bifidobacterium that secretes a siderophore, and detecting the presence of unabsorbed lactose in the gastrointestinal tract, where a decrease in the presence of unabsorbed lactose after administration of the Bifidobacterium indicates treatment of the lactase deficiency.
- 17. The method of claim 16 further comprising growing the Bifidobacterium under iron limited conditions before administration.
- 18. The method of claim 16 wherein the animal is a human.
- 19. The method of claim 16 wherein the gastrointestinal tract is the large intestine.
- 20. A method for establishing a Bifidobacterium flora in the gastrointestinal tract of an animal comprising administering to an animal a Bifidobacterium that secretes a siderophore, and measuring the presence of the Bifidobacterium in the gastrointestinal tract of the animal after administration.
- 21. The method of claim 20 further comprising growing the Bifidobacterium under iron limited conditions before administration.
- 22. The method of claim 20 wherein the gastrointestinal tract is the large intestine.
- 23. The method of claim 20 wherein the animal is a human.
- 24. The method of claim 23 wherein the human is an infant selected from the group consisting of an immature infant, a premature infant, and a mature infant.
- 25. The method of claim 23 wherein the administration occurs after the human has undergone antibiotic therapy.
- 26. The method of claim 23 wherein the administration occurs after the human has undergone chemotherapy.
- 27. A method for preventing the replication of microbes in a food, the method comprising adding to the food a Bifidobacterium that secretes siderophore.
- 28. A method for decreasing the risk of colon cancer comprising administering to an animal a Bifidobacterium that secretes a siderophore, and detecting the presence of aberrant crypt foci in the colon of the animal, where a lower number of aberrant crypt foci relative to an animal not administered the Bifidobacterium indicates a decrease in the risk of colon cancer.
- 29. A composition for inhibiting the replication of a microbe in the gastrointestinal tract of an animal, the composition comprising a Bifidobacterium that secretes siderophore.
- 30. A method for obtaining a siderophore from a Bifidobacterium, the method comprising incubating a Bifidobacterium under iron limited conditions, and isolating the siderophore.
- 31. A method for preparing a siderophore, the method comprising incubating a Bifidobacterium under iron limited conditions, and sterilizing the culture.
- 32. The method of claim 31 wherein the culture is sterilized by removing essentially all water from the culture.
- 33. A composition comprising a siderophore obtained from a Bifidobacterium, wherein the composition is sterile.
- 34. An isolated siderophore obtained from a Bifidobacterium.
- 35. An isolated siderophore that binds Fe2+, the siderophore obtained from a Bifidobacterium.
- 36. A method for decreasing the amount of free iron in a composition, the method comprising adding to a composition a siderophore obtained from a Bifidobacterium.
- 37. A method for decreasing the amount of free iron in a composition, the method comprising adding to a composition an isolated siderophore obtained from a Bifidobacterium.
- 38. A method for inhibiting the replication of a microbe in a composition, the method comprising adding to a composition a siderophore obtained from a Bifidobacterium.
- 39. A method for inhibiting the replication of a microbe in a composition, the method comprising adding to a composition an isolated siderophore obtained from a Bifidobacterium.
- 40. A method for altering the expression of a siderophore in a Bifidobacterium, the method comprising incubating under iron limited conditions a Bifidobacterium that does not secrete a siderophore, and selecting for a Bifidobacterium that replicates in the iron limited condition.
CONTINUING APPLICATION DATA
[0001] This application claims the benefit of U.S. Provisional Application Ser. No. 60/212,273, filed Jun. 19, 2000, which is incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60212273 |
Jun 2000 |
US |